0022-534 7/92/1482-0342$03.00/0 THE JOURNAL OF UROLOGY Copyright© 1992 by AMERICAN UROLOGICAL ASSOCIATION, INC.
Vol. 148, 342-345, August 1992 Printed in U.S.A.
TRANSRECTAL MI CROWAVE HYPERTHERMIA FOR ADVAN CED PROSTATE CANCER: LONG-TERM CLINICAL RESULTS FRANCESCO MONTORSI, GIORGIO GUAZZONI, RENZO COLOMBO, LAURA GALLI, FRANCO BERGAMASCHI AND PATRIZIO RIGATTI From the Institute of Human Anatomy, University of Milan School of Medicine, and Department of Urology and Unit of Epidemiology and Medical Statistics, Institute San Raffaele, Milan, Italy
ABSTRACT
Transrectal microwave hyperthermia was applied to 46 stages Dl and D2 prostate cancer patients to treat urinary symptoms and local pain unrelieved by total androgen ablation therapy. Hyperthermia was administered in 10, 60-minute sessions twice a week for 5 weeks. A calculated intraprostatic temperature of 43.5 ± 0.5C was maintained throughout the treatment. At 2 years the mean residual urine volume was significantly decreased (p
Vol. 148, 342-345, August 1992 Printed in U.S.A.
TRANSRECTAL MI CROWAVE HYPERTHERMIA FOR ADVAN CED PROSTATE CANCER: LONG-TERM CLINICAL RESULTS FRANCESCO MONTORSI, GIORGIO GUAZZONI, RENZO COLOMBO, LAURA GALLI, FRANCO BERGAMASCHI AND PATRIZIO RIGATTI From the Institute of Human Anatomy, University of Milan School of Medicine, and Department of Urology and Unit of Epidemiology and Medical Statistics, Institute San Raffaele, Milan, Italy
ABSTRACT
Transrectal microwave hyperthermia was applied to 46 stages Dl and D2 prostate cancer patients to treat urinary symptoms and local pain unrelieved by total androgen ablation therapy. Hyperthermia was administered in 10, 60-minute sessions twice a week for 5 weeks. A calculated intraprostatic temperature of 43.5 ± 0.5C was maintained throughout the treatment. At 2 years the mean residual urine volume was significantly decreased (p
